Advertisement

Vascular endothelial growth factor gene polymorphisms in Korean patients with premature ovarian failure

      Abstract

      Objective

      To study the association of vascular endothelial growth factor (VEGF) polymorphisms (−2578C>A, −1154G>A, −634G>C, and 936C>T) with premature ovarian failure (POF) in Korean patients.

      Study design

      Prospective case–control study. One hundred and thirty five patients with POF and confirmed serum follicle-stimulating hormone levels of >40 IU/L before the age of 40 years and 120 healthy controls with at least one live birth, regular menstrual cycles, and karyotype 46, XX.

      Results

      POF patients exhibited significantly different frequencies of the VEGF −1154GA genotype (odds ratio [OR], 2.002; 95% confidence interval [CI], 1.116–3.592; P = 0.019), and −2578CA+AA/−1154GA+AA combination genotype (OR, 1.805; 95% CI, 1.013–3.217; P = 0.044) compared to the control group. The frequency of the −2578A/−1154A haplotype (OR, 1.647; 95% CI, 1.017–2.677; P = 0.041) was significantly higher in the POF group than in the control group.

      Conclusion

      The VEGF −1154G>A mutation, −2578CA+AA/−1154GA+AA combination genotype, and −2578A/−1154A haplotype are significantly associated with POF in Korean women.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      References

        • Conway G.S.
        Premature ovarian failure.
        Br Med Bull. 2000; 56: 643-649
        • Goswami D.
        • Conway G.S.
        Premature ovarian failure.
        Horm Res. 2007; 68: 196-202
        • Kalantaridou S.N.
        • Davis S.R.
        • Nelson L.M.
        Premature ovarian failure.
        Endocrinol Metab Clin North Am. 1998; 27: 989-1006
        • Shelling A.N.
        Premature ovarian failure.
        Reproduction. 2010; 140: 633-641
        • Harry L.E.
        • Paleolog E.M.
        From the cradle to the clinic: VEGF in developmental, physiological, and pathological angiogenesis.
        Birth Defects Res C Embryo Today. 2003; 69: 363-374
        • Ferrara N.
        • Gerber H.P.
        • LeCouter J.
        The biology of VEGF and its receptors.
        Nat Med. 2003; 9: 669-676
        • Brogan I.J.
        • Khan N.
        • Isaac K.
        • Hutchinson J.A.
        • Pravica V.
        • Hutchinson I.V.
        Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene.
        Hum Immunol. 1999; 60: 1245-1249
        • Cosín R.
        • Gilabert-Estellés J.
        • Ramón L.A.
        • et al.
        Vascular endothelial growth factor polymorphisms (−460C/T, and +405G/C, and 936C/T) and endometriosis: their influence on vascular endothelial growth factor expression.
        Fertil Steril. 2009; 92: 1214-1220
        • Lambrechts D.
        • Storkebaum E.
        • Morimoto M.
        • et al.
        VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death.
        Nat Genet. 2003; 34: 383-394
        • Mohammadi M.
        • Bazrafshani M.R.
        • Day P.J.
        • Ollier W.E.
        Vascular endothelial growth factor production is regulated by gene polymorphisms.
        Iran J Immunol. 2009; 6: 119-129
        • Shahbazi M.
        • Fryer A.A.
        • Pravica V.
        • et al.
        Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection.
        J Am Soc Nephrol. 2002; 13: 260-264
        • Watson C.J.
        • Webb N.J.
        • Bottomley M.J.
        • Brenchley P.E.
        Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production.
        Cytokine. 2000; 12: 1232-1235
        • Shimizu T.
        • Iijima K.
        • Miyabayashi K.
        • et al.
        Effect of direct ovarian injection of vascular endothelial growth factor gene fragments on follicular development in immature female rats.
        Reproduction. 2007; 134: 677-682
        • Shimizu T.
        • Iijima K.
        • Ogawa Y.
        • Miyazaki H.
        • Sasada H.
        • Sato E.
        Gene injections of vascular endothelial growth factor and growth differentiation factor-9 stimulate ovarian follicular development in immature female rats.
        Fertil Steril. 2008; 89: 1563-1570
        • Shimizu T.
        • Sato E.
        Manipulation of ovarian follicle development by injecting vascular endothelial growth factor (VEGF) gene.
        Reprod Biol. 2005; 5: 257-268
        • Taylor P.D.
        • Wilson H.
        • Hillier S.G.
        • Wiegand S.J.
        • Fraser H.M.
        Effects of inhibition of vascular endothelial growth factor at time of selection on follicular angiogenesis, expansion, development and atresia in the marmoset.
        Mol Hum Reprod. 2007; 13: 729-736
        • Coulam C.B.
        • Jeyendran R.S.
        Vascular endothelial growth factor gene polymorphisms and recurrent pregnancy loss.
        Am J Reprod Immunol. 2008; 59: 301-305
        • Lee H.H.
        • Hong S.H.
        • Shin S.J.
        • Ko J.J.
        • Oh D.
        • Kim N.K.
        Association study of vascular endothelial growth factor polymorphisms with the risk of recurrent spontaneous abortion.
        Fertil Steril. 2010; 93: 1244-1247
        • Papazoglou D.
        • Galazios G.
        • Papatheodorou K.
        • et al.
        Vascular endothelial growth factor gene polymorphisms and idiopathic recurrent pregnancy loss.
        Fertil Steril. 2005; 83: 959-963
        • Fischer C.
        • Mazzone M.
        • Jonckx B.
        • Carmeliet P.
        FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?.
        Nat Rev Cancer. 2008; 8: 942-956
        • Fukuhara S.
        • Sako K.
        • Noda K.
        • Zhang J.
        • Minami M.
        • Mochizuki N.
        Angiopoietin-1/Tie2 receptor signaling in vascular quiescence and angiogenesis.
        Histol Histopathol. 2010; 25: 387-396
        • Iruela-Arispe M.L.
        • Dvorak H.F.
        Angiogenesis: a dynamic balance of stimulators and inhibitors.
        Thromb Haemost. 1997; 78: 672-677
        • Lohela M.
        • Bry M.
        • Tammela T.
        • Alitalo K.
        VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.
        Curr Opin Cell Biol. 2009; 21: 154-165
        • Rusnati M.
        • Presta M.
        Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies.
        Curr Pharm Des. 2007; 13: 2025-2044
        • Redmer D.A.
        • Reynolds L.P.
        Angiogenesis in the ovary.
        Rev Reprod. 1996; 1: 182-192
        • Reynolds L.P.
        • Grazul-Bilska A.T.
        • Redmer D.A.
        Angiogenesis in the female reproductive organs: pathological implications.
        Int J Exp Pathol. 2002; 83: 151-163
        • Ferrara N.
        • Chen H.
        • Davis-Smyth T.
        • et al.
        Vascular endothelial growth factor is essential for corpus luteum angiogenesis.
        Nat Med. 1998; 4: 336-340
        • Lee E.J.
        • Oh B.
        • Lee J.Y.
        • Kimm K.
        • Park J.M.
        • Baek K.H.
        Association study between single nucleotide polymorphisms in the VEGF gene and polycystic ovary syndrome.
        Fertil Steril. 2008; 89: 1751-1759
        • Gentilini D.
        • Somigliana E.
        • Vigano P.
        • Vignali M.
        • Busacca M.
        • Di Blasio A.M.
        The vascular endothelial growth factor +405G>C polymorphism in endometriosis.
        Hum Reprod. 2008; 23: 211-215
        • Cooke J.P.
        NO and angiogenesis.
        Atheroscler Suppl. 2003; 4: 53-60
        • Hefler L.A.
        • Tempfer C.B.
        • Bashford M.T.
        • et al.
        Polymorphisms of the angiotensinogen gene, the endothelial nitric oxide synthase gene, and the interleukin-1beta gene promoter in women with idiopathic recurrent miscarriage.
        Mol Hum Reprod. 2002; 8: 95-100
        • Hillermann R.
        • Carelse K.
        • Gebhardt G.S.
        The Glu298Asp variant of the endothelial nitric oxide synthase gene is associated with an increased risk for abruptio placentae in pre-eclampsia.
        J Hum Genet. 2005; 50: 415-419
        • Huber A.
        • Grimm C.
        • Jirecek S.
        • et al.
        Polymorphisms of the Nos3 gene and unexplained late intrauterine fetal death.
        Eur J Obstet Gynecol Reprod Biol. 2005; 122: 151-155
        • Suryanarayana V.
        • Rao L.
        • Kanakavalli M.
        • Padmalatha V.
        • Deenadayal M.
        • Singh L.
        Recurrent early pregnancy loss and endothelial nitric oxide synthase gene polymorphisms.
        Arch Gynecol Obstet. 2006; 274: 119-124
        • Yoshimura T.
        • Yoshimura M.
        • Tabata A.
        • Yasue H.
        • Okamura H.
        The missense Glu298Asp variant of the endothelial nitric oxide synthase gene is strongly associated with placental abruption.
        Hum Genet. 2001; 108: 181-183